Search for dissertations about: "C1 inhibitor"

Showing result 1 - 5 of 10 swedish dissertations containing the words C1 inhibitor.

  1. 1. Novel monogalactoside galectin inhibitor scaffolds : Guiding selectivity with heteroaromatic interactions

    Author : Alexander Dahlqvist; Centrum för analys och syntes; []
    Keywords : NATURVETENSKAP; NATURAL SCIENCES; Galectin; Galectin inhibitor; Heterocycles; C-glycoside; Medicinal chemistry; Organic chemistry; Hydroboration; Diastereoselective; Galactose;

    Abstract : Carbohydrates are involved in many cellular processes, and most biomolecules are glycosylated. Thesemodifications are used in biological systems as information carriers, helping regulate organization on the cell surfaceand interactions between cells and the environment. READ MORE

  2. 2. The Plasma Contact System : New Functional Insights from a Hemostatic and Thrombotic Perspective

    Author : Jennie Bäck; Bo Nilsson; Kristina Nilsson Ekdahl; Ulla Hedner; Uppsala universitet; []
    Keywords : MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Contact activation; factor XII; platelets; coagulation; antithrombin; C1 inhibitor; hemostasis; biomarkers; vascular disease.; Klinisk immunologi; Clinical Immunology;

    Abstract : The physiological role of the plasma contact system still remains a partial enigma. The aim of the presented work was to expand our understanding of the plasma contact system, focusing on its physiological activation and function, principally from a hemostatic perspective. It also explored contact system activation under pathological conditions. READ MORE

  3. 3. Novel treatments of glioblastoma in experimental models

    Author : Karolina Förnvik; Neurokirurgi; []
    Keywords : MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Experimental glioma models; Glioblastoma; Complement system; C1 esterase inhibitor; ITPP; CRP; Glioma cells;

    Abstract : One of the major problems with malignant brain tumours, such as glioblastoma multiforme, is that despite being able to remove the major bulk of the tumour through surgery and treating the patients with chemotherapy and radiotherapy, we know that tumour cells have already spread throughout the brain. Furthermore, we now know that the glioblastoma cells effectively suppress the patients’ own anti-tumour response. READ MORE

  4. 4. CYSTATIN C AND NEUROENDOCRINE DIFFERENTIATION IN THE MALE REPRODUCTIVE SYSTEM AND IN PROSTATE CANCER

    Author : Thomas Jiborn; Malmö Urologisk cancerforskning; []
    Keywords : MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Urology; androgen deprivation therapy; cysteine protease inhibitor; neuroendocrine differentiation; cysteine protease; male reproductive tract; prostate cancer; nefrologi; Urologi; nephrology;

    Abstract : Cystatins are endogenous protease inhibitors that regulate the proteolytic activities of family C1 (papain-like) cysteine proteases, such as human cathepsins B, H, K, L, and S. Cystatin C shows the fastest inhibition and the highest affinity of all cystatins towards lysosomal cysteine proteases in general and is widespread in human tissues and body fluids. READ MORE

  5. 5. HEMOPHILIA A AND B WITH SPECIAL REFERENCE TO INHIBITOR DEVELOPMENT AND EXPERIMENTAL STUDIES OF FACTORS VIII AND IX

    Author : Karin Knobe; Enheten för pediatrisk hematologi; []
    Keywords : MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Haematology; inhibitors; mutations; Factor IX; Factor VIII; coagulation; hemophilia A and B; extracellular fluids; Hematologi; extracellulära vätskor;

    Abstract : The general objective of the research underlying this dissertation was to conduct clinical and basic scientific studies to further elucidate the hemophilia and the coagulation process, with the goal of improving the care of families with these disorders. More specific aims were to evaluate epidemiological, genetic, clinical, and biochemical aspects of the development of inhibitors (antibodies) against FVIII and FIX in Swedish patients with hemophilia A and B (papers I, II, and III). READ MORE